2026-06-03T19:49:01Z https://www.peertechzpublications.org/oai-pmh

oai:www.peertechzpublications.org:10.17352/2455-5495.000023 2017-06-19 PTZ.ARDM:VOL3

Effectiveness and Tolerability of Febuxostat vs Allopurinol in patients with Chronic Kidney Disease (CKD) on Conservative Therapy Filomena Panza Chiara RalliEnnio Duranti<p>Uric&nbsp; Acid&nbsp; appears&nbsp; to&nbsp; be&nbsp; one&nbsp; of&nbsp; the&nbsp; most&nbsp; important&nbsp; prognostic&nbsp; markers&nbsp; and&nbsp; one&nbsp; of&nbsp; the&nbsp; principal&nbsp; risk&nbsp; factors&nbsp; for&nbsp; cardiovascular&nbsp; diseases.&nbsp; The&nbsp; aim&nbsp; of&nbsp; our&nbsp; study&nbsp; was&nbsp; to&nbsp; assess&nbsp; three&nbsp; groups&nbsp; of&nbsp; patients: a first&nbsp; group&nbsp; treated&nbsp; with&nbsp; Allopurinol&nbsp; (AL),&nbsp; a&nbsp; second&nbsp; group&nbsp; not&nbsp; adequately&nbsp; controlled&nbsp; by&nbsp; treatment&nbsp; with AL&nbsp; or&nbsp; allergic&nbsp; to&nbsp; AL&nbsp; switched&nbsp; to&nbsp; treatment&nbsp; with&nbsp; Febuxostat&nbsp; (AL/FB)&nbsp; and&nbsp; a&nbsp; third&nbsp; group&nbsp; of&nbsp; naive&nbsp; patients immediately treated with Febuxostat (FB). The effectiveness and tolerability of both drugs were therefore assessed over time.</p><p><strong>Materials and methods:</strong> 44 patients, with CKD in conservative therapy, were divided into 3 groups. A group of 20 patients (AL) with well controlled uricemic values (serum uric acid &lt; 6 mg/dl); a group of 12 patients&nbsp; (AL/FB)&nbsp; with&nbsp; not&nbsp; well&nbsp; controlled&nbsp; uricemic&nbsp; values&nbsp; (serum&nbsp; uric&nbsp; acid&nbsp; concentration&nbsp; &gt;&nbsp; 6.0&nbsp; mg&nbsp; /&nbsp; dl) and / or intolerant to AL that were switched to treatment with FB, then a group of 12 naive patients (FB) treated immediately with FB. At time 0,3,6,9,12,18,24 months, all patients were monitored as regards: serum uric acid, renal function parameters, serum electrolytes, hemoglobin, lipid profile, blood glucose, glycated hemoglobin, proteinuria 24 hours,parathyroid hormone (PTH), C Reactive Protein (CRP). The doses of anti-uric acid administered drug were also evaluated. All the patients underwent a monitoring of blood pressure (BP), heart rate (HR) and body mass index (BMI). </p> Archives of Renal Diseases and Management - Peertechz Publications 2017-06-19 Research Article https://doi.org/10.17352/2455-5495.000023 en Copyright © Filomena Panza et al.